Invictus RG’s Exact Sciences EXAS Stock Holding History

Invictus RG’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-4,919	Closed	-$258K	–	270
2017 Q4	$258K	Buy	+4,919	New	+$263K	0.27%	212

Other funds holding EXAS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invictus RG's EXAS Position: Q1 2018 in Review

Invictus RG sold out of Exact Sciences (EXAS) in Q1 2018, closing a stake of 4,919 shares — an estimated $258K sold.

Invictus RG first reported a position in EXAS in Q4 2017 and held it in 1 quarter. The position peaked at $258K in Q4 2017. 319 funds tracked by Wall St. Rank hold EXAS as of Q1 2018.

Invictus RG reported no remaining Exact Sciences position as of Q1 2018 after selling out during the quarter.
Invictus RG sold 4,919 Exact Sciences shares in Q1 2018, an estimated $258K.
Invictus RG first reported a position in Exact Sciences in Q4 2017 and held it in 1 quarter.
Invictus RG's Exact Sciences position peaked at $258K in Q4 2017.
319 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2018.

Based on Invictus RG's 13F filing for Q1 2018, filed 14 May 2018.